Scleroderma autoimmune disease. Ace myhomework myhomework writers acemywork

Clinical Pharmacology: Protein Tyrosine Kinase Inhibitor, inhibits BCR-ABL tyrosine kinase, half life of 18 hours, 40 hours for the metabolite, peak plasma time is 2-4 hours with 98% bioavailability, 95% protein bound, metabolised by CYP3A4; clearance is